Regenerative medicine: looking backward 10 years further on.

The last decade has seen considerable changes in the Regenerative Medicine industry, but unfortunately the hope for numerous treatments that 'replace or regenerate human cells, tissues or organs to restore or establish normal function' has not yet emerged. In contrast to this, there have been major advances in the field of cellular immunotherapy though some do not consider these to be Regenerative Medicines. Regulatory changes have in some cases improved the route to a marketing license but they have not been matched by clarification of the complex, national reimbursement processes for cell-based treatments and this has adversely affected a number of leading Regenerative Medicine Companies. The review considers the direction that the industry may go in the future in relation to scientific, manufacturing and clinical strategies which may improve the rate of success of new therapies..